Washington University School of Medicine

Digital Commons@Becker
Open Access Publications
2019

Sex modulates the ApoE ε4
4 effect on brain tau deposition
measured by 18F-AV-1451 PET in individuals with mild cognitive
impairment
Min Liu
Peking University

Manish D. Paranjpe
Harvard University

Xin Zhou
University of Pennsylvania

Phan Q. Duy
Yale University

Manu S. Goyal
Washington University School of Medicine in St. Louis

See next page for additional authors

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Recommended Citation
Liu, Min; Paranjpe, Manish D.; Zhou, Xin; Duy, Phan Q.; Goyal, Manu S.; Benzinger, Tammie L.S.; Lu, Jie;
Wang, Rongfu; and Zhou, Yun, ,"Sex modulates the ApoE ε4 effect on brain tau deposition measured by
18F-AV-1451 PET in individuals with mild cognitive impairment." Theranostics. 9,17. . (2019).
https://digitalcommons.wustl.edu/open_access_pubs/8031

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been
accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker.
For more information, please contact vanam@wustl.edu.

Authors
Min Liu, Manish D. Paranjpe, Xin Zhou, Phan Q. Duy, Manu S. Goyal, Tammie L.S. Benzinger, Jie Lu, Rongfu
Wang, and Yun Zhou

This open access publication is available at Digital Commons@Becker: https://digitalcommons.wustl.edu/
open_access_pubs/8031

Theranostics 2019, Vol. 9, Issue 17

Ivyspring
International Publisher

Research Paper

4959

Theranostics

2019; 9(17): 4959-4970. doi: 10.7150/thno.35366

Sex modulates the ApoE ε4 effect on brain tau
deposition measured by 18F-AV-1451 PET in individuals
with mild cognitive impairment
Min Liu1, 2*, Manish D Paranjpe3*, Xin Zhou4, Phan Q. Duy5, Manu S Goyal6, Tammie L.S. Benzinger6, Jie
Lu7, Rongfu Wang1, Yun Zhou1,2,6; for the Alzheimer’s Disease Neuroimaging Initiative
1.
2.
3.
4.
5.
6.
7.

Department of Nuclear Medicine, Peking University First Hospital, Beijing, China
The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, United States of
America
Harvard-MIT Program in Health Sciences and Technology, Harvard Medical School, Boston, MA, United States of America
Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, PA, United States of America
Medical Scientist Training Program, Yale University School of Medicine, New Haven, CT, United States of America
Mallinckrodt Institute of Radiology, Washington University in St. Louis School of Medicine, St. Louis, MO, United States of America
Department of Radiology, Xuanwu Hospital of Capital Medical University, Beijing, China

* These authors contributed equally to this work.
 Corresponding authors: Yun Zhou, Mallinckrodt Institute of Radiology, Washington University in St. Louis School of Medicine, 510 Kingshighway Blvd., St.
Louis, MO 63110, USA; Tel: (314)2737792; Fax: (314)3628555; Email: yunzhou@wustl.edu; Rongfu Wang, Department of Nuclear Medicine, Peking University
First Hospital, No. 8 Xishiku St., Xicheng District, Beijing, 100034, China; rongfu_wang@163.com.
© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/).
See http://ivyspring.com/terms for full terms and conditions.

Received: 2019.03.31; Accepted: 2019.05.20; Published: 2019.07.09

Abstract
The strongest genetic risk factor for Alzheimer’s disease (AD) is the Apolipoprotein E type 4 allele (ApoE
ε4). The interaction between sex and ApoE ε4 carrier status on AD risk remains an area of intense
investigation. We hypothesized that sex modulates the relationship between ApoE ε4 carrier status and
brain tau deposition (a quantitative endophenotype in AD) in individuals with mild cognitive impairment
(MCI).
Methods: Preprocessed 18F-AV-1451 tau and 18F-AV-45 amyloid PET images, T1-weighted structural
magnetic resonance imaging (MRI) scans, demographic information, and cerebrospinal fluid (CSF)
total tau (t-tau) and phosphorylated tau (p-tau) measurements from 108 MCI subjects in the Alzheimer’s
Disease Neuroimaging Initiative (ADNI) database were included. After downloading pre-processed
images from ADNI, an iterative reblurred Van Cittertiteration partial volume correction (PVC) method
was applied to all PET images. MRIs were used for PET spatial normalization. Regions of interest (ROIs)
were defined in standard space, and standardized uptake value ratio (SUVR) images relative to cerebellum
were computed. ApoE ε4 by sex interaction analyses on 18F-AV-1451 and CSF tau (t-tau, p-tau) were
assessed using generalized linear models. The association between 18F-AV-1451 SUVR and CSF tau (t-tau,
p-tau) was assessed.
Results: After applying PVC and controlling for age, education level and global cortical 18F-AV-45 SUVR,
we found that the entorhinal cortex, amygdala, parahippocampal gyrus, posterior cingulate, and occipital
ROIs exhibited a significant ApoE ε4 by sex interaction effect (false discovery rate P < 0.1) among MCI
individuals. We also found a significant ApoE ε4 by sex interaction effect on CSF t-tau and p-tau.
18F-AV-1451 SUVR in the 5 ROIs with ApoE ε4 by sex interaction was significantly correlated with CSF
p-tau and t-tau.
Conclusions: Our findings suggest that women are more susceptible to ApoE ε4-associated
accumulation of neurofibrillary tangles in MCI compared to males. Both CSF tau (p-tau, t-tau) and brain
tau PET are robust quantitative biomarkers for studying ApoE ε4 by sex effects on brain tau deposition in
MCI participants.
Key words: tau deposition, ApoE ε4, mild cognitive impairment, 18F-AV-1451, partial volume correction
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Introduction
Alzheimer’s disease (AD) is the leading cause of
dementia in the elderly. AD is characterized by the
presence of amyloid β (Aβ) plaques and
hyperphosphorylated tau neurofibrillary tangles
(NFT) which are thought to be responsible for
neurodegeneration
and
subsequent
cognitive
dysfunction. The lack of therapies for AD highlights
the clinical need to better understand the
environmental, genetic, and demographic risk factors
underlying
disease
risk
and
progression.
Apolipoprotein E type 4 allele (ApoE ε4) is the largest
genetic risk factor for AD development [1, 2]. ApoE ε4
carriers exhibit faster cognitive decline [3, 4],
increased amyloid β deposition [5], higher NFT
density [6] and increased glucose hypometabolism [7]
than ApoE ε4 non-carriers. In addition to genetics, sex
is an important demographic factor that influences
AD risk. Compared to males, females are reported to
have higher incidence of AD [8], worse cognitive
functions when they have AD [9], and increased AD
pathology [10, 11]. The interaction between sex and
ApoE ε4 carrier status on cognitive decline remains an
area of intense investigation. Sex has been shown to
modulate the effects of ApoE ε4 in AD clinical
conversion risk. Strikingly, healthy older females and
females with mild cognitive impairment (MCI) who
carry the ApoE ε4 allele are more likely to develop AD
than their male counterparts [12, 13]. Female ApoE ε4
carriers exhibit higher tau levels in the cerebrospinal
fluid (CSF) compared to male carriers [13], especially
among amyloid positive females [14].
Neuroimaging shows promise in early AD
diagnosis. The novel PET tracer 18F-AV-1451 (also
called 18F-T807, 18F-flortaucipir) showed higher
selectivity of >25 fold for paired helical filaments of
hyperphosphorylated tau (PHF-tau) compared to
amyloid β [15]. The 18F-AV-1451 radiotracer displays
favorable pharmacokinetic properties, good overlap
with PHF-tau deposits as described by Braak staging
[16], and strong association with dementia severity
[17]. These characteristics make 18F-AV-1451 a useful
imaging biomarker for studying AD and dementia.
The analysis of ApoE ε4 by sex interaction in tau
PET imaging is critical for understanding the role of
sex and ApoE ε4 on brain tau PET as a quantitative
AD endophenotype. Uncovering regions with ApoE
by sex interaction in MCI patients will also help in the
development of precision-medicine therapies targeted
to sex and ApoE-stratified patient groups in MCI.
Further, this analysis will also help to define more
appropriate sex and ApoE-stratified imaging-based
endpoints for clinical trials in AD. In this study we
examined whether sex modulates the ApoE ε4 effect
on brain tau deposition measured by 18F-AV-1451 PET
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among MCI subjects in the Alzheimer’s Disease
Neuroimaging Initiative (ADNI).

Methods
Participants
In this cross-sectional study, we collected
subjects with available ApoE ε4 genotyping
information and 18F-AV-1451 PET, 18F-AV-45 PET and
T1-weighted structural magnetic resonance imaging
(MRI) scans from ADNI. 108 MCI subjects were
included. For every subject, only his or her most
recent 18F-AV-1451 PET and matched T1-weighted
MRI scan in the same scanning visit were included.
The most recent 18F-AV-45 PET scan was also
included for each subject.
All MCI subjects had a subjective memory
concern reported by a clinician, abnormal memory
function on the education-adjusted Logical Memory II
subscale, and a clinical dementia rating of 0.5 or
higher. Further, all MCI subjects were deemed to have
cognitive and functional performance that was
sufficiently intact to not merit a diagnosis of dementia
by the site physician.
A full list of study inclusion/exclusion criteria
can be found at https://adni.loni.usc.edu/wpcontent/uploads/2008/07/adni2-procedures-manual
.pdf.

ApoE Genotyping, CSF Aβ, t-tau, and p-tau
Assessments
Peripheral blood (10 mL) was collected from
study participants to be used for ApoE ε4 genotyping.
Restriction enzyme isoform genotyping was
performed on extracted DNA to test for the presence
of the ApoE ε4 genotype, as described previously [18].
ApoE ε4 carriers were defined as individuals with at
least one ε4 allele (either ε4/ ε4, ε4/ ε3 or ε4/ ε2).
Non-carriers were defined as individuals with no ε4
allele.
CSF samples were acquired through lumbar
puncture as previously described by ADNI:
http://adni.loni.usc.edu/methods/documents/.
Concentration of CSF biomarkers including Aβ, t-tau,
and p-tau, were assessed using the xMAP Luminex
platform (Luminex Corp., Austin, TX) platform. For
more details regarding CSF specimen collection and
analyte measurement please refer to ADNI.

MRI and PET Acquisition and Processing
T1-weighted
MRI
and
pre-processed
18
and
F-AV-45 PET images were
downloaded
from
the
ADNI
database
(http://adni.loni.usc.edu/). The PET images had
been previously aligned, averaged, reoriented and
then interpolated into a standard image and voxel size
18F-AV-1451
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(image volume 160×160×96, 1.5×1.5×1.5 mm in x, y,
z), and smoothed to a uniform resolution of 8 mm in
full width at half maximum (FWHM) by the ADNI
consortium.
We further processed the downloaded PET
images using Statistical Parametric Mapping (SPM12,
Wellcome Department of Imaging Neuroscience,
London, United Kingdom) and MATLAB (The
MathWorks Inc.). Briefly, all PET images were
coregistered to matched structural MRI images. The
MRI images were normalized to standard Montreal
Neurologic Institute (MNI) space using SPM12 and
VBM8 toolbox with a MRI template (image volume:
121×145×121, voxel size: 1.5×1.5×15 mm in x, y, z).
The transformation parameters determined by MRI
spatial normalization were then applied to the
coregistered PET images for PET spatial
normalization. Regions of interest (ROIs) including
cerebellum gray matter for reference tissue were
manually drawn on the MRI template using PMOD
(PMOD Technologies Ltd., Zürich, Switzerland) in
standard MNI space. ROI templates developed
previously in the Johns Hopkins Department of
Radiology were used in this study [7, 19-21]. To
measure whole brain amyloid deposition, a global
cortex was defined as a union of orbital frontal,
prefrontal, superior frontal, lateral temporal, parietal,
posterior precuneus, occipital, anterior cingulate, and
posterior cingulate. Standard uptake value ratio
(SUVR) images were calculated relative to the
cerebellum. ROI SUVRs were obtained by calculating
mean SUVR within ROIs on the SUVR images in the
MNI space.
A partial volume correction (PVC) was applied
to the processed 18F-AV-1451 and 18F-AV-45 PET
images
to
correct
or
minimize
potential
underestimation in PET measurement due to low
image resolution, especially for small tissues as the
amygdala and striatum. In brief, an iterative reblurred
Van Cittertiteration method was used for PVC on the
mean images, where a 3-D Gaussian kernel of 8 mm
FWHM was used for spatial smoothing function h,
step length α=1.5, and the iteration was stopped if
relative percent change of PVC images < 1% [22].

Statistical Analysis
To increase statistical power, a ROI feature
selection method was used to select regions of interest
for ApoE by sex interaction analyses. Specifically, we
selected 13 cortical and subcortical regions including
the
entorhinal
cortex,
amygdala,
fusiform,
parahipppocampal gyrus, occipital, lateral temporal,
parietal, posterior precuneus, posterior cingulate,
orbital frontal cortex, prefrontal cortex, superior
frontal, and anterior cingulate, using ROI templates

4961
we developed previously in the Johns Hopkins
Department of Radiology [7, 19-21]. These 13 regions
were either previously determined by our group to
significantly differ in 18F-AV-1451 PET SUVR between
cognitively normal, MCI and AD patients [23] or were
required to define global cortical amyloid [19]. All
false discovery rate (FDR) corrections were applied
using these 13 ROIs. A depiction of the 13 ROIs used
in the study are presented in MNI space in Figure S1
in the Supplement.
Statistical Analysis System (SAS version 9.4, SAS
Institute, Inc) was used for all statistical analyses. Two
generalized linear models (GLMs) with and without
controlling for global cortical 18F-AV-45 SUVR were fit
for ApoE ε4 carrier status by sex interaction analyses:
ROI_SUVR (18F-AV-1451) ~ Age + Educational level +
Global cortex_SUVR (18F-AV-45) + Sex:ApoE ε4 status
ROI_SUVR (18F-AV-1451) ~ Age + Educational level +
Sex:ApoE ε4 status
The GLM models were fit for each ROI SUVR
and the ApoE ε4 by sex term was evaluated to identify
regions with significant ApoE ε4 by sex interaction
effect on 18F-AV-1451 uptake. P values of ApoE ε4 by
sex term were corrected for multiple comparisons
using a Benjamini-Hochberg method with FDR < 10%
defined as significant, consistent with previous
studies [24-26] .
Estimated marginal means (LS-means) of ApoE
ε4 carriers and non-carriers stratified by sex were
calculated using the interactive models in order to
investigate the effects of ApoE ε4 on 18F-AV-1451 in
women and men separately. Differences in LS-means
between ApoE ε4 carriers and non-carriers in males
and females separately were evaluated. In addition,
we also evaluated differences in LS-means between
males and females in ApoE ε4 carrier and non-carrier
groups separately. P values were corrected for
multiple comparisons using the Tukey-Kramer
method [27] (maximum experimentwise error rate P
<0.05).
Similar to the brain tau PET analyses, ApoE ε4 by
sex interaction effects on CSF t-tau and p-tau were
analyzed by fitting a GLM and controlling for age and
education level. We fit additional models controlling
for either global cortical 18F-AV-45 amyloid SUVR or
CSF amyloid.
To investigate whether the regional 18F-AV-1451
was significantly associated with AD-relevant
biomarkers such as CSF t-tau and p-tau, the
correlation between CSF tau (t-tau, p-tau) and
regional 18F-AV-1451 was analyzed by linear
regression.
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Data Availability
All datasets used during the current study are
available
in
the
ADNI
repository,
http://adni.loni.usc.edu/.

Results
Cohort Characteristics
A total of 108 ADNI subjects (38 ApoE ε4 carriers
and 70 ApoE ε4 non-carriers; 42 women and 66 men)
were included in the study. Participant characteristics
are summarized in the Table 1. The mean±SD age of
our study participants was 78 ± 7.4 years. No
significant differences in age, MMSE score, and global
cortical amyloid SUVR were found between women
and men in the ApoE ε4 carrier (two-sample t-test P >
0.05) and non-carrier groups (two-sample t-test P >
0.05). A moderate difference in education level was
found between women and men in the ApoE ε4
carriers (two-sample t-test P = 0.01) and non-carriers
(two-sample t-test P =0.02) groups. Chi-squared
analysis revealed no significant differences in the
proportion of ApoE ε4ε4/ ε4ε3/ ε4ε2 genotype
individuals between men and women (P = 0.38). A
full list of demographic variables with statistics are
listed in Table 1.

ApoE ε4 by sex interaction on 18F-AV-1451
ROI SUVR
on

ROIs with significant ApoE ε4 by sex interaction
SUVR were identified with and

without controlling for global cortical amyloid (Table
2) using the 13 ROIs described in the Methods. In MCI
individuals, we found the entorhinal cortex,
amygdala,
parahippocampal
gyrus,
posterior
cingulate, and occipital ROIs to exhibit a significant
ApoE ε4 carrier status by sex effect (FDR P < 0.1) after
applying PVC and controlling for global cortical
amyloid uptake measured by 18F-AV-45 PET. Notably,
only the entorhinal cortex reached significance (FDR P
< 0.1) in the non-PVC data (Table 2). For the GLM
without controlling for global cortical amyloid
uptake, we found the entorhinal cortex, amygdala,
fusiform,
parahippocampal
gyrus,
posterior
cingulate, and occipital ROIs to exhibit a significant
ApoE ε4 by sex effect (FDR P < 0.1; Table 2) in both
PVC and non-PVC data.
Mean SUVR images with and without PVC from
MCI females and males are displayed in Figure 1.
Figure 1A visually suggests that PVC increases
18F-AV-1451 SUVR contrast between ApoE ε4 carriers
and non-carriers in the entorhinal cortex, amygdala,
fusiform,
parahippocampal
gyrus,
posterior
cingulate, and occipital ROIs compared to non-PVC
mean SUVR images (Figure 1B). Figure 1 also
suggests that presence of the ApoE ε4 allele is
associated with more tau deposition in women
compared to men. Quantified SUVR from 18F-AV-1451
images with PVC in ROIs stratified by sex and ApoE
status are displayed in Figure 2.

18F-AV-1451

Table 1. Study cohort characteristics
Characteristic
Age, year
Education, years
White race, No (%)
MMSE Score
global cortical amyloid SUVR
CSF Aβ-42 (pg/mL)
CSF t-tau (pg/mL)
CSF p-tau (pg/mL)
Interval between 18F-AV-1451
and 18F-AV-45, month
ε4 ε4/ ε4 ε3/ ε4 ε2 in
ApoE ε4 carriers

Mean±SD [Range]
Women
Women
ApoE ε4+
ApoE ε4 –
(n=15)
(n=27)
74.4±6.8
79.3±6.4
[61.2-84.5]
[68.1-92.6]
14.1±2.7
15.4±2.5
[8.0-20.0]
[12.0-19.0]
15(100)
24(89)
26.8±2.4
28.0±2.4
[23.0-30.0]
[19.0-30.0]
1.56±0.35
1.20±0.21
[1.02-2.35]
[0.96-1.69]
933.0±398.1
1326.6±425.4
[469.0-1700]
[426-1700]
380.5±160.8
248.5±89.2
[234.6-750.0]
[100.2-443.5]
36.5±16.6
21.6±7.9
[20.6-71.6]
[8.7-38.6]
5.5±7.3
4.3±5.1
[0.0-27.0]
[0.0-16.0]
3/11/1

Men
ApoE ε4+
(n=23)
76.7±8.4
[59.6-90.3]
16.8±3.2
[12.0-20.0]
22(96)
27.4±2.6
[22.0-30.0]
1.47±0.35
[0.99-2.20]
845.3±435.0
[248.1-1700]
262.7±82.4
[115.4-426.4]
24.9±8.3
[10.5-42.3]
3.78±4.51
[0.0-13.0]
7/16/0

Men
ApoE ε4 –
(n=43)
79.8±7.1
[67.8-93.2]
17.0±2.9
[8.0-20.0]
43(100)
28.1±2.0
[23.0-30.0]
1.28±0.40
[0.91-3.12]
1272.3±415.6
[396.6-1700]
240.7±103.2
[121.4-553.5]
21.6±10.2
[9.9-52.3]
3.30±4.85
[0.0-17.0]

P valuea
Women
ε4+ vs ε4 -

Men
ε4+ vs ε4 -

ApoE ε4+
Women vs Men

ApoE ε4 Women vs Men

0.03

0.12

0.39

0.78

0.12

0.76

0.01

0.02

0.18
0.13

0.17
0.22

0.41
0.45

0.03
0.80

0.001

0.06

0.43

0.28

0.01

<0.001

0.55

0.62

0.01

0.41

0.03

0.75

0.01

0.22

0.03

1

0.54

0.70

0.37

0.40

0.38

a P value was defined using a two-sample t test to compare age, education level, MMSE Score, global cortical amyloid SUVR, CSF biomarkers and AV1451-AV45 scanning
interval between ApoE ε4 carriers and ApoE ε4 non-carriers in male and female subgroups, and between males and females in ApoE ε4 carrier and ApoE ε4 non-carrier
subgroups. A Chi-square test was used to compare differences in proportion of Caucasian participants between ApoE ε4 carriers and ApoE ε4 non-carriers in male and
female subgroups, and between males and females in ApoE ε4 carrier and ApoE ε4 non-carrier subgroups. A Chi-squared test was used to compare proportion of ε4ε4/ ε4ε3/
ε4ε2 genotype individuals between males and females in the ApoE ε4 carrier group.
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Table 2. ApoE ε4 carrier status by sex interaction effect in MCI participants
Model
Adjusted for
global cortical
amyloid level

Characteristic

Entorhinal Cortex
Amygdala
Fusiform
Parahippocampal
Posterior Cingulate
Occipital
Orbital Frontal
Prefrontal
Superior Frontal
Lateral Temporal
Parietal
Posterior Precuneus
Anterior Cingulate
Not adjusted for Entorhinal Cortex
global cortical
Amygdala
amyloid level
Fusiform
Parahippocampal
Posterior Cingulate
Occipital
Orbital Frontal
Prefrontal
Superior Frontal
Lateral Temporal
Parietal
Posterior Precuneus
Anterior Cingulate

PVC
Standardized
β(95%CI) a
0.39(0.14-0.64)
0.30(0.03-0.55)
0.25(0.00-0.50)
0.29(0.03-0.54)
0.31(0.04-0.57)
0.34(0.09-0.58)
0.16(-0.12-0.45)
0.07(-0.2-0.35)
0.01(-0.26-0.28)
0.18(-0.07-0.43)
0.18(-0.07-0.45)
0.21(-0.07-0.48)
-0.11(-0.38-0.16)
0.43(0.18-0.69)
0.34(0.07-0.60)
0.31(0.05-0.58)
0.35(0.08-0.61)
0.35(0.08-0.63)
0.40(0.14-0.67)
0.19(-0.09-0.47)
0.10(-0.18-0.39)
0.06(-0.22-0.34)
0.26(-0.01-0.53)
0.24(-0.03-0.51)
0.25(-0.03-0.52)
-0.09(-0.36-0.17)

ApoE ε4 x sex
P value b
0.003
0.03
0.05
0.03
0.03
0.01
0.25
0.61
0.96
0.15
0.15
0.14
0.42
0.001
0.01
0.02
0.01
0.01
0.003
0.19
0.46
0.67
0.06
0.08
0.08
0.49

ApoE ε4 x sex
Adjusted P valuec
0.03
0.07
0.11
0.07
0.07
0.06
0.33
0.66
0.96
0.22
0.22
0.22
0.50
0.01
0.03
0.05
0.03
0.03
0.02
0.25
0.53
0.67
0.12
0.12
0.12
0.53

non-PVC
Standardized
β(95%CI) a
0.34(0.10-0.59)
0.26(0.00-0.52)
0.21(-0.04-0.46)
0.26(0.01-0.51)
0.25(-0.02-0.51)
0.30(0.05-0.55)
0.06(-0.23-0.340
0.03(-0.25-0.31)
-0.07(-0.34-0.20)
0.15(-0.10-0.40)
0.13(-0.13-0.39)
0.16(-0.11-0.43)
-0.13(-0.41-0.14)
0.40(0.14-0.65)
0.30(0.04-0.56)
0.28(0.00-0.55)
0.32(0.06-0.59)
0.30(0.02-0.57)
0.37(0.10-0.64)
0.09(-0.20-0.37)
0.07(-0.22-0.35)
-0.01(-0.30-0.27)
0.22(-0.05-0.49)
0.19(-0.09-0.46)
0.21(-0.07-0.48)
-0.11(-0.39-0.16)

ApoE ε4 x sex
P value b
0.01
0.05
0.10
0.04
0.07
0.02
0.68
0.83
0.59
0.24
0.33
0.24.
0.34
0.003
0.03
0.04
0.02
0.04
0.01
0.55
0.64
0.93
0.11
0.18
0.15
0.43

ApoE ε4 x sex
Adjusted P valuec
0.09
0.16
0.22
0.16
0.18
0.11
0.74
0.83
0.70
0.40
0.44
0.40
0.44
0.04
0.09
0.10
0.08
0.09
0.04
0.65
0.69
0.93
0.20
0.26
0.24
0.56

β value is coefficient of ApoE ε4 by sex interaction, 95% CI represents the 95% confidence interval of the ApoE ε4 by sex coefficient.
P value as defined using a generalized linear model to detect significant ApoE ε4 by sex interaction effect in MCI subjects. Age and education were included as covariates.
Global cortical amyloid SUVR was also included as a covariate in the upper results.
c Adjusted P value as defined using Benjamini–Hochberg procedure to control FDR.
a

b

Upon comparing SUVR from ApoE ε4 carriers
with ApoE ε4 non-carriers, we found a significant
ApoE ε4 effect in the entorhinal cortex, amygdala,
fusiform, parahippocampus, posterior cingulate,
occipital cortex, lateral temporal, parietal, and
posterior precuneus among women (two-sample
t-test, P < 0.05). In contrast, no ROIs exhibit a
significant ApoE ε4 effect in men.

ApoE ε4 and sex-stratified analysis
Given that we saw significant ApoE ε4 by sex
interaction effects in MCI patients, we analyzed the
effect of ApoE ε4 on 18F-AV-1451 stratified by sex
(Table 3) after adjusting for education, age and
amyloid. Specifically, we analyzed the difference in
marginal means between ApoE ε4 carriers and
non-carriers stratified by sex. All 5 ROIs (entorhinal
cortex, amygdala, parahippocampal gyrus, posterior
cingulate and occipital ROIs) with significant ApoE ε4
by sex interaction effect displayed a significant ApoE
ε4 effect in women when the marginal means were not
adjusted for global cortical 18F-AV-45 SUVR. The
entorhinal cortex, amygdala, parahippocampal gyrus,
and posterior cingulate retained a significant ApoE ε4
effect in women when the marginal means were
adjusted for global cortical 18F-AV-45 SUVR (FDR <
0.1). No ROIs exhibit a significant ApoE ε4 effect in
men.

We also analyzed the difference in marginal
means between males and females stratified by ApoE
ε4 carrier status (Table 3). Four out of the 5 ROIs
(entorhinal cortex, parahippocampal gyrus, posterior
cingulate and occipital ROIs) with significant ApoE ε4
by sex interaction showed a significant sex effect in
ApoE ε4 carriers with or without adjusting marginal
means for global cortical 18F-AV-45 SUVR. These
regions retained a significant sex effect in ApoE ε4
carriers when adjusted for global cortical 18F-AV-45
SUVR. In contrast, no ROIs exhibit a significant sex
effect in ApoE ε4 non-carriers. Non-PVC based results
are presented in Table S1 in the Supplement.

Association between regional 18F-AV1451 and
CSF p-tau and t-tau
We identified 97 ADNI subjects with CSF t-tau
and p-tau measurements. We observed that CSF p-tau
was significantly associated with the PVC based
18F-AV-1451 SUVR in the entorhinal cortex, amygdala,
fusiform,
parahippocampal
gyrus,
posterior
cingulate, occipital, lateral temporal, and orbitofrontal
cortex (P < 0.05; Figure 3). The orbitofrontal cortex
failed to reach significance in the non-PVC data (P =
0.07). CSF t-tau was also significantly associated with
18F-AV-1451 PVC PET in all 8 of these regions. The
posterior cingulate (P = 0.08) and orbitofrontal cortex
(P = 0.07) failed to reach significance in the non-PVC
data.
http://www.thno.org
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Figure 1. Mean 18F-AV-1451 PET SUVR images with and without partial volume correction in MCI individuals. Mean images were generated by computing the
mean of images from ApoE ε4 carriers and non-carriers separately. Partial volume corrected images (A) show increased contrast and spatial resolution compared to non-PVC
images (B). Both PVC and non-PVC images show an interaction effect between sex and ApoE ε4 status. Note that the mean images are averaged over all participants in each
sex-ApoE ε4 group.

We also analyzed potential ApoE ε4 by sex
interaction effects in CSF t-tau and p-tau. We found a

significant ApoE ε4 by sex interaction effect on CSF
t-tau and p-tau with and without controlling for
http://www.thno.org
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amyloid in the 97 ADNI subjects with CSF t-tau and
p-tau measurements (Table 4). Mean CSF t-tau and
p-tau levels stratified by sex and ApoE ε4 carrier
status are displayed graphically in Figure 4.

Discussion and Conclusion
This cross-sectional analysis provides evidence
of a significant ApoE ε4 carrier status by sex
interaction effect on brain tau measured using
18F-AV-1451 PET in MCI patients. Using 108 ADNI
participants, we observed a significant ApoE ε4 by sex
interaction effect (FDR P < 0.1) on 18F-AV-1451 tau
binding in the entorhinal cortex, amygdala,
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parahippocampal gyrus, posterior cingulate, and
occipital cortex among MCI individuals. Further, our
ROI based results suggest that PVC improved PET
spatial resolution and contrast in this study.
Specifically, we observe a near but not significant
ApoE ε4 by sex interaction effect in AV-1451 binding
without PVC (entorhinal cortex was significant
without PVC) (Table 2). Also, as a result of applying
PVC, we are confident that changes in 18F-AV-1451
reported here are genuine metabolic changes
associated with ApoE ε4 rather than due to
volume-related or technical biases.

Figure 2. Regions with significant ApoE ε4 effect on 18F-AV-1451 SUVR. Bar graphs showing ROIs SUVR (mean with error bars depicting SD) of tau 18F-AV-1451 PET
imaging between ApoE ε4 carriers and non-carriers in regions with significant ApoE ε4 effect. P value were defined using a two-sample t-test to compare SUVR between ApoE
ε4 carriers and ApoE ε4 non-carriers in male and female subgroups, and between males and females in ApoE ε4 carrier and ApoE ε4 non-carrier subgroups. *** P < 0.001; ** P
< 0.01; * P < 0.05. Note: Short significance lines indicate comparison between ApoE ε4 carriers and non-carriers using a two-sample t-test. Long significance lines indicate
comparison between men and women using a two-sample t-test.
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Table 3. Effects of ApoE ε4 on 18F-AV-1451 stratified by sex with PVC
Model

Region

LS-meana
Women
ApoE ε4+

Women
ApoE ε4 -

Men
ApoE ε4+

Men
ApoE ε4 -

Adjusted for
global cortical
amyloid level

Entorhinal Cortex
Amygdala
Fusiform
Parahippocampal
Posterior Cingulate
Occipital
Orbital Frontal
Prefrontal
Superior Frontal
lateral temporal
Parietal
Posterior Precuneus
Anterior Cingulate
Entorhinal Cortex
Amygdala
Fusiform
Parahippocampal
Posterior Cingulate
Occipital
Orbital Frontal
Prefrontal
Superior Frontal
Lateral Temporal
Parietal
Posterior Precuneus
Anterior Cingulate

1.96
1.79
1.39
1.48
1.46
1.31
1.23
1.16
1.17
1.38
1.25
1.35
0.94
2.04
1.85
1.45
1.54
1.51
1.36
1.24
1.18
1.20
1.44
1.29
1.39
0.95

1.46
1.33
1.20
1.25
1.21
1.18
1.17
1.14
1.14
1.24
1.11
1.17
0.97
1.41
1.29
1.16
1.21
1.18
1.15
1.16
1.13
1.12
1.20
1.08
1.15
0.97

1.48
1.52
1.20
1.26
1.20
1.14
1.13
1.09
1.10
1.23
1.10
1.21
0.89
1.53
1.55
1.24
1.29
1.23
1.17
1.14
1.10
1.13
1.26
1.12
1.23
0.89

1.44
1.40
1.20
1.23
1.21
1.19
1.14
1.10
1.08
1,21
1.08
1.18
0.88
1.42
1.38
1.18
1.22
1.19
1.17
1.13
1.09
1.07
1.19
1.06
1.17
0.88

Not adjusted for
global cortical
amyloid level

P valueb
Women
ε4+ vs ε4 <0.001
0.003
0.08
0.02
0.05
0.11
0.61
0.98
0.98
0.19
0.21
0.17
0.88
<0.001
<0.001
0.002
<0.001
0.003
0.003
0.31
0.73
0.49
0.01
0.01
0.03
0.97

Men
ε4+ vs ε4 0.97
0.60
1
0.98
1
0.63
1
0.99
0.97
0.98
0.99
0.98
0.99
0.69
0.28
0.75
0.63
0.96
1
1
1
0.67
0.53
0.69
0.79
0.95

ApoE ε4+
Women vs Men
0.001
0.13
0.08
0.03
0.04
0.01
0.14
0.37
0.69
0.12
0.13
0.34
0.75
<0.001
0.10
0.06
0.02
0.02
0.01
0.11
0.30
0.57
0.09
0.09
0.26
0.70

ApoE ε4 Women vs Men
1
0.88
1
1
1
1
0.70
0.51
0.49
0.91
0.91
1
0.04
1
0.78
0.99
1
1
0.95
0.77
0.63
0.71
1
1
0.99
0.05

LS-mean indicates the least squares (marginal) means in each ApoE ε4-sex groups after adjusting for age and education. Global cortical amyloid SUVR was also included as
a covariate in the upper results.
b All P values correspond to pairwise LS-mean differences after correcting for multiple comparisons using the Tukey-Kramer method.
a

Table 4. ApoE ε4 by sex interaction effect on CSF t-tau and p-tau in MCI participants
Model
Not adjusted for global cortical F-AV-45
Adjusted for CSF amyloid level
Adjusted for global cortical 18F-AV-45 (non-PVC)
Adjusted for global cortical 18F-AV-45 (PVC)
18

CSF t-tau
Standardized
β(95%CI) a
0.35(0.06-0.62)
0.30(0.03-0.55)
0.33(0.04-0.60)
0.33(0.04-0.60)

ApoE ε4 x sex
P value b
0.02
0.03
0.02
0.03

CSF p-tau
Standardized
β(95%CI) a
0.36(0.08-0.63)
0.26(0.00-0.52)
0.33(0.05-0.60)
0.33(0.05-0.59)

ApoE ε4 x sex
P value b
0.01
0.05
0.02
0.02

β value is coefficient of ApoE ε4 by sex interaction, 95% CI represents the 95% confidence interval of the ApoE ε4 by sex coefficient.
P value as defined using a generalized linear model to detect significant ApoE ε4 by sex interaction effect in MCI subjects. Age and education were included as covariates in
each model. Additional covariates of CSF amyloid or global cortical AV45 were added were added as indicated.
a

b

A recently published study analyzed ApoE ε4 by
sex interaction effects on 18F-AV-1451 PET using
healthy elderly individuals [28]. The authors found a
significant ApoE ε4 by sex interaction effect in a
meta-ROI containing the entorhinal cortex, inferior
temporal cortex, amygdala, fusiform gyrus, and
parahippocampal cortex, but no significant ApoE ε4
by sex interaction effect on the entorhinal cortex
alone. In contrast to this prior study that investigated
only cognitively normal individuals, our study
focused on a cohort with MCI demonstrating that this
ApoE ε4 by sex interaction on tauopathy persists in
individuals progressing towards symptomatic AD.
This result is particularly important when considering
clinical trials aimed at an MCI cohort. Furthermore,
our study identifies this interaction using different
imaging processing methods and additional ROIs,
suggesting that the ApoE ε4 by sex interaction on
tauopathy identified by both studies is robust to

different methodologies within the ADNI cohort.
Importantly, in the present study we controlled
for global cortical amyloid load measured by
18F-AV-45 PET. Recent work shows that amyloid
might increase brain tau through mechanisms
involving Sirt3 [29], GSK3β [30, 31] or Cdk5 [32]. In
imaging studies involving brain tau, it is important to
control for the potential confounding effects of
amyloid on tau. In our data, we observe a significant
ApoE ε4 by sex interaction on AV-1451 PET after
controlling for global cortical amyloid burden,
suggesting that the ApoE ε4 allele exerts a
sex-dependent effect on brain tau, independent of
amyloidosis. These results are supported by recent
biochemical studies demonstrating that ApoE ε4
triggers higher neuronal levels of phospho-tau
independent of amyloid [33]. Further, transgenic mice
overexpressing ApoE ε4 exhibit greater hippocampal
phospho-tau and exhibit deficits in tau clearance
http://www.thno.org
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independent of amyloid pathology [34]. It should be
noted however that in spite of possible
amyloid-independent
mechanisms,
additional
statistical models analyzing amyloid by sex
interaction effects suggest that our originally-reported
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ApoE by sex interaction effect on brain tau in the
occipital cortex may be partly due to amyloid as
females may be more susceptible to amyloid-induced
tauopathy in this region (Result S1 in the
Supplement).

Figure 3. Correlations between regional 18F-AV-1451 SUVR and CSF p-tau measurements. Line graphs showing correlation between CSF p-tau (ng/mL) and
18F-AV-1451 SUVR. Both non-PVC and PVC PET data are shown for ROIs in the entorhinal cortex (A), amygdala (B), fusiform (C), parahippocampus gyrus (D), posterior cingulate
(E), occipital (F), lateral temporal (G), and orbitofrontal cortex (H). Fitted lines, P-values, and 95% confidence intervals are displayed from linear regression models.
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Figure 4. ApoE ε4 by sex interaction effects on CSF t-tau, p-tau in MCI individuals. Plots of mean with error bar (standard deviation) showing CSF t-tau (A) and p-tau
(B) in each sex-ApoE ε4 subgroup. Dashed lines indicate the direction of the ApoE ε4 effect. This graphical depiction of ApoE ε4 by sex interaction effects on CSF t-tau and p-tau
is supported by statistical results in Table 4.

Our ApoE ε4 and sex-stratified analysis help
explain the nature of ApoE ε4 by sex interaction effect
in 4 out of the 5 ROIs with a significant ApoE ε4 by sex
interaction effect (entorhinal cortex, parahippocampal
gyrus, posterior cingulate and occipital ROIs). In these
ROIs, there is no sex difference in 18F-AV-1451 among
ApoE ε4 non-carriers. However, in ApoE ε4 carriers,
we observed a significant sex effect (Table 3). This
suggests that the presence of ApoE ε4 allele is
associated with significantly higher levels of brain tau
deposition in females as compared to males.
As a further measure of clinical relevance of our
study, we found that 18F-AV-1451 signal in all 5 ROIs
with significant ApoE ε4 by sex interaction effect is
also associated with CSF p-tau (Figure 3). Previous
studies have found an ApoE ε4 by sex interaction
effect on CSF p-tau, a well-studied biomarker in AD
[13, 14]. Our data adds to the clinical validity of CSF
p-tau by elucidating a brain-based correlate. Overall,
by integrating 18F-AV-1451 PET and CSF p-tau data,
we find a robust relationship between brain tau and
biomarker changes outside the brain.
A possible additional explanation for the sex
differences identified in our study might be that
women could be cognitively more resilient to the
effects of tauopathy. Recent findings suggest that
women may have on average “younger brain
predicted age” based on structural brain MRI [35] and
metabolic brain PET imaging [36]. Similarly, younger
individuals with autosomal dominant AD show
markedly increased tauopathy compared to late onset
AD individuals despite similar degrees of cognitive
impairment [37]. It is possible then that due to
increased brain resilience, women with more ApoE ε4
mediated tauopathy than men can nevertheless
remain cognitively normal as demonstrated by
Buckley et al. [28] or mildly impaired as demonstrated
in our results. In order to further test the hypothesis
that women may be more resilient to higher loads of
tauopathy than men in MCI, we refitted our ApoE ε4
by sex interaction models controlling for MMSE score

(Table S2 in the Supplement). These results show that
all five regions with significant ApoE ε4 by sex
interaction effect in MCI in the original model (Table
2) are also significant when controlling for MMSE
score. This analysis further suggests that compared to
men, women experience greater ApoE ε4-mediated
tauopathy while remaining at the same level of
cognitive deficit. Notably the idea that sex differences
in brain resilience to AD might help explain our
findings is not mutually exclusive from the idea that
sex also influences the risk to AD pathology; both sex
brain differences and ApoE status might carry both
risks and resilience to neurodegeneration and
dementia, as well as vascular disease. Further studies
to disentangle these potentially complex relationships
are needed.
This study has clinical implications for precision
medicine. Our results demonstrate that female ApoE
ε4 carriers exhibit greater tau accumulation than their
male counterparts. Several anti-tau clinical trials are
underway [38, 39]. In designing clinical trials, our
results suggest that the dosage of anti-tau antibodies
should be modified by ApoE ε4-sex group. In future
efforts to validate tau as a quantitative
endophenotype or clinical outcome measure, studies
should stratify patient cohorts by ApoE ε4-sex group.
Likewise,
in
mechanistic
studies
exploring
tau-dependent mechanisms underlying ApoE
ε4-mediated AD risk, results should be analyzed
separately in males and females.
As a limitation to our study, it should be noted
that our study contained a small percentage (35%) of
ApoE ε4 carriers. While this proportion is in line with
previously published studies and the larger ADNI
cohort [40, 41], possible selection biases may be
present in our cohort. Future studies should be
conducted in larger cohorts to minimize selection
biases. Our study is however balanced in terms of
proportion of female and male ApoE ε4 carriers
(females: 36% ApoE ε4 carriers vs males: 35% ApoE ε4
carriers; P = 0.93, Chi-Square test).
http://www.thno.org
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